NEW YORK (360Dx) – VolitionRx announced today that it has signed agreements with academic partners to conduct large-scale clinical studies of its Nu.Q colorectal cancer screening platform in the Asia Pacific region.
The Nu.Q platform is based on the company's Nucleosomics technology for identifying and quantifying nucleosome structural features such as histone modifications and variations, DNA methylation patterns, and nucleosome-protein adducts.
Under the terms of the agreements, researchers from National Taiwan University and Japan's National Cancer Screening Hospital will conduct two studies of Nu.Q in multicountry, multicenter and multiethnic Asian subject cohorts. The first will include 5,000 asymptomatic colorectal cancer screening subjects, and the second will include up to 2,000 symptomatic colorectal cancer patients.
VolitionRx noted that the studies will test and validate the platform for the detection and diagnosis of colorectal cancer for marketing — not regulatory — purposes.
"At a cost of approximately $2.55 million payable over three years, these large-scale studies are in line with Volition's other great value studies and demonstrate our commitment to conducting large yet cost-effective trials worldwide to drive the acceptance of our products," Jasmine Kway, CEO of Singapore Volition, said in a statement. "These studies are pivotal for Volition's strategy for the Asia Pacific region where incidence of colorectal cancer is increasing."
VolitionRx noted that it has recently partnered with the National University of Singapore to conduct a 719-subject study of Nu.Q. The company is also conducting studies of the platform in approximately 45,000 European subjects and 13,500 US subjects in collaboration with various research institutes.